KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE

被引：662

作者：

de Boer, Ian H. ^{[1
,2
]}

Rossing, Peter ^{[3
,4
,5
,6
]}

Caramori, M. Luiza ^{[7
,8
,9
,10
,11
]}

Chan, Juliana C. N. ^{[12
,13
]}

Heerspink, Hiddo J. L. ^{[14
,15
,16
,17
]}

Hurst, Clint ^{[18
]}

Khunti, Kamlesh ^{[19
,20
,21
,22
,23
,24
,25
]}

Liew, Adrian ^{[26
,27
,28
,29
,30
,31
,32
,33
,34
]}

Michos, Erin D. ^{[35
,36
,37
,38
,39
,40
,41
,42
,43
]}

Navaneethan, Sankar D. ^{[44
,45
,46
,47
]}

Olowu, Wasiu A. ^{[48
,49
]}

Sadusky, Tami ^{[50
,51
,52
,53
,54
,55
]}

Tandon, Nikhil ^{[56
,57
,58
,59
,60
,61
,62
,63
]}

Tuttle, Katherine R. ^{[64
,65
,66
,67
,68
,69
,70
,71
,72
,73
,74
]}

Wanner, Christoph ^{[75
,76
,77
,78
,79
]}

Wilkens, Katy G. ^{[80
,81
,82
]}

Zoungas, Sophia ^{[83
,84
,85
,86
,87
,88
]}

Jadoul, Michel ^{[89
,90
,91
,92
]}

Winkelmayer, Wolfgang C. ^{[92
,93
,94
,95
,96
,97
,98
,99
]}

Tonelli, Marcello A. ^{[100
,101
,102
,103
,104
,105
,106
]}

Craig, Jonathan C. ^{[107
,108
,109
,110
,111
,112
,113
,114
]}

Strippoli, Giovanni F. M. ^{[115
,116
]}

Tunnicliffe, David J. ^{[117
,118
,119
]}

Higgins, Gail Y. ^{[120
,121
,122
,123
]}

Natale, Patrizia ^{[124
,125
,126
]}

Cooper, Tess E. ^{[127
,128
]}

Willis, Narelle S. ^{[129
,130
]}

机构：

[1] Univ Washington, Epidemiol, Seattle, WA 98195 USA

[2] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA

[3] Steno Diabet Ctr Res Team, Copenhagen, Denmark

[4] Univ Copenhagen, Diabet Angiopathy, Copenhagen, Denmark

[5] European Diabet Nephropathy Study Grp, Copenhagen, Denmark

[6] Danish Natl Diabet Registry, Copenhagen, Denmark

[7] Univ Minnesota, Minneapolis, MN USA

[8] Univ Minnesota, Med Ctr, Joint Commiss Accredited Inpatient Diabet Serv, Minneapolis, MN 55455 USA

[9] NIH R01 Grant Study Protect Factors Diabet Kidney, Copenhagen, Denmark

[10] NKF Kidney Dis Outcomes Qual Initiat KDOQI Work G, Copenhagen, Denmark

[11] Diabet Nephropathy Subcomm ADA Sci Sess, Copenhagen, Denmark

[12] Chinese Univ Hong Kong, Med & Therapeut, Hong Kong, Peoples R China

[13] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China

[14] Univ Med Ctr Groningen, Clin Trials & Personalized Med, Groningen, Netherlands

[15] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

[16] Univ New South Wales, Sydney, NSW, Australia

[17] George Inst Global Hlth, Sydney, NSW, Australia

[18] US Army, Washington, DC 20310 USA

[19] Univ Leicester, Primary Care Diabet & Vasc Med, Leicester, Leics, England

[20] UK Natl Inst Hlth Res NIHR Appl Res Collaborat AR, Leicester, Leics, England

[21] Ctr Ethn Hlth Res, Leicester, Leics, England

[22] Real World Evidence Unit, Leicester, Leics, England

[23] UK Govt Sci Advisory Grp Emergencies SAGE, Leicester, Leics, England

[24] SAGE Ethn Subpanel, Leicester, Leics, England

[25] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia

[26] Mt Elizabeth Novena Hosp, Kidney & Transplant Practice, Singapore, Singapore

[27] ISPD, Singapore, Singapore

[28] ISN, Execut Comm & Council, Singapore, Singapore

[29] ISN Oceania Southeast Asia Reg Board, Singapore, Singapore

[30] ISN End Stage Kidney Failure Strategy Dialysis Su, Singapore, Singapore

[31] ISN Renal Disaster Preparedness Working Grp, Singapore, Singapore

[32] ISN Dialysis Working Grp, Singapore, Singapore

[33] ISN Continuing Med Educ CME Comm, Singapore, Singapore

[34] Asia Pacific Soc Nephrol APSN CME Comm, Hong Kong, Peoples R China

[35] Johns Hopkins Univ, Div Cardiol, Med, Baltimore, MD USA

[36] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[37] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Womens Cardiovasc Hlth, Baltimore, MD USA

[38] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Prevent Cardiol, Baltimore, MD USA

[39] Board Directors Amer Soc Prevent Cardiol ASPC, Baltimore, MD USA

[40] Amer Coll Cardiol ACC Prevent Leadership Council, Washington, DC USA

[41] ACCs Clin Qual Approval Comm CPAC, Washington, DC USA

[42] AHA Funding Comm, Washington, DC USA

[43] Natl Inst Hlth Funded Multiethn Study Atheroscler, Bethesda, MD USA

[44] Baylor Coll Med, Nephrol Sect, Clin Res, Houston, TX 77030 USA

[45] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA

[46] NKF, New York, NY USA

[47] ASN, New York, NY USA

[48] OAUTHC, Dept Pediat, Pediat Nephrol & Hypertens Unit, Osun, Nigeria

[49] Obafemi Awolowo Univ, Dept Pediat & Child Hlth, Pediat Nephrol, Ife, Nigeria

[50] Univ Washington, Res Finance & Operat, Seattle, WA 98195 USA

来源：

KIDNEY INTERNATIONAL | 2022年 / 102卷 / 05期

关键词：

angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker; chronic kidney disease; dialysis; evidence-based; GLP-1 receptor agonist; glycemia; glycemic monitoring; glycemic targets; guideline; HbAlc; hemodialysis; KDIGO; lifestyle; metformin; models of care; nutrition; renin-angiotensin system; self-management; SGLT2; inhibitor; systematic review; teambased care; CONVERTING-ENZYME-INHIBITION; DIETARY-PROTEIN RESTRICTION; GLUCOSE COTRANSPORTER 2; GLOMERULAR-FILTRATION-RATE; INTENSIFIED MULTIFACTORIAL INTERVENTION; ESTABLISHED CARDIOVASCULAR-DISEASE; INSULIN-DEPENDENT DIABETICS; MODERATE SODIUM RESTRICTION; ASSESSING GLYCEMIC CONTROL; URINARY ALBUMIN EXCRETION;

D O I：

10.1016/j.kint.2022.06.008

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating diabetes and CKD. Topic areas for which recommendations are updated include: Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. Previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) have been deemed current and their content has remained unchanged. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and the strength of recommendations followed the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

引用

页码：S1 / S127

页数：127

共 467 条

[11] Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors
Ahuja, TS
Freeman, D
Mahnken, JD
Agraharkar, M
Siddiqui, M
Memon, A
[J]. AMERICAN JOURNAL OF NEPHROLOGY, 2000, 20 (04) : 268 - 272
[12] Direct and Indirect Effects of Obesity on the Kidney
Alicic, Radica Z.
Patakoti, Ramu
Tuttle, Katherine R.
[J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2013, 20 (02) : 121 - 127
[13] Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation
Alnasrallah, Basil
Goh, Tze Liang
Chan, Lai Wan
Manley, Paul
Pilmore, Helen
[J]. BMC NEPHROLOGY, 2019, 20 (1)
[14] 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022
American Diabetes Association Professional Practice Committee
[J]. DIABETES CARE, 2022, 45 : S144 - S174
[15] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
American Diabetes Association Professional Practice Committee
[J]. DIABETES CARE, 2022, 45 : S125 - S143
[16] 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022
American Diabetes Association Professional Practice Committee
[J]. DIABETES CARE, 2022, 45 : S83 - S96
[17] Amod A, 2020, DIABETES THER, V11, P53, DOI [10.2337/dci19-0066, 10.1007/s13300-019-00715-x]
[18] Andad V, 2013, COCHRANE DB SYST REV, V9
[19] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Anker, Stefan D.
Butler, Javed
Filippatos, Gerasimos
Ferreira, Joao P.
Bocchi, Edimar
Boehm, Michael
Brunner-La Rocca, Hans-Peter
Choi, Dong-Ju
Chopra, Vijay
Chuquiure-Valenzuela, Eduardo
Giannetti, Nadia
Gomez-Mesa, Juan Esteban
Janssens, Stefan
Januzzi, James L.
Gonzalez-Juanatey, Jose R.
Merkely, Bela
Nicholls, Stephen J.
Perrone, Sergio V.
Pina, Ileana L.
Ponikowski, Piotr
Senni, Michele
Sim, David
Spinar, Jindrich
Squire, Iain
Taddei, Stefano
Tsutsui, Hiroyuki
Verma, Subodh
Vinereanu, Dragos
Zhang, Jian
Carson, Peter
Lam, Carolyn Su Ping
Marx, Nikolaus
Zeller, Cordula
Sattar, Naveed
Jamal, Waheed
Schnaidt, Sven
Schnee, Janet M.
Brueckmann, Martina
Pocock, Stuart J.
Zannad, Faiez
Packer, Milton
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1451 - 1461
[20] [Anonymous], 1995, BMJ, V310, P83

← 1 2 3 4 5 6 7 8 9 10 →